Market Overview

UPDATE: Goldman Sachs Downgrades Humana to Sell on Healthcare Reform Headwinds

Share:
Related HUM
Humana To Begin Covering Exact Science's Cologuard In 2017
Benzinga's Top Downgrades
Why Trump And The GOP Must Replace ObamaCare Now, In 2 Charts (Investor's Business Daily)

Goldman Sachs lowered its rating on Humana (NYSE: HUM) from Neutral to Sell.

Goldman Sachs said, "With this report, we downgrade Humana to Sell from Neutral, reflecting that the company derives a majority of its earnings, by our estimate, from the MA products that face significant headwinds and uncertainties as funding and other changes from health reform roll through. We think this will make P/E multiple recovery (expansion) difficult for HUM and there is downside risk to earnings as we enter the critical phase of MA payment transitions in 2014-2017. That said, our Sell rating on HUM is relative to our Neutral coverage view of Managed Care."

Humana closed at $76.16 on Tuesday.

Latest Ratings for HUM

DateFirmActionFromTo
Dec 2016Cantor FitzgeraldDowngradesBuyHold
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!